| P50 | author | John Wagstaff | Q58065490 |
| P2093 | author name string | R J Scheper | |
| | H M Pinedo | |
| | T D de Gruijl | |
| | S A Luykx-de Bakker | |
| P2860 | cites work | Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 |
| | Human tumor antigens recognized by T lymphocytes | Q24678508 |
| | Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 |
| | Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution | Q24679240 |
| | Dendritic cells and the control of immunity | Q27860918 |
| | Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 |
| | Tolerance, danger, and the extended family | Q29547532 |
| | Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes | Q29619437 |
| | The dendritic cell system and its role in immunogenicity | Q29619870 |
| | Immunotherapy of cancer with dendritic-cell-based vaccines | Q32066652 |
| | A new foreign policy: MHC class I molecules monitor the outside world | Q34398620 |
| | Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow | Q36215287 |
| | Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1 | Q36364968 |
| | Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 |
| | CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha | Q36367113 |
| | Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified | Q36367631 |
| | Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures | Q36376739 |
| | Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor | Q36377402 |
| | Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases | Q36380718 |
| | Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity | Q36380749 |
| | A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels | Q36499151 |
| | CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells | Q37698653 |
| | Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions | Q40881143 |
| | Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 |
| | Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo | Q41079157 |
| | Dendritic cells in immune response induction | Q41185715 |
| | Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens | Q41226490 |
| | Dendritic cells: origin and differentiation | Q41305811 |
| | Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines | Q41415648 |
| | Dendritic cell surface molecules. A proliferating field. | Q41586732 |
| | The host-tumor immune conflict: from immunosuppression to resistance and destruction | Q41633001 |
| | Dendritic cells as adjuvants for immune-mediated resistance to tumors | Q41649620 |
| | Phenotypic and functional differences between human dendritic cells derived in vitro from hematopoietic progenitors and from monocytes/macrophages. | Q43611931 |
| | Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. | Q45138741 |
| | Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells | Q45884859 |
| | Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 |
| | T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions | Q47982736 |
| | Help for cytotoxic-T-cell responses is mediated by CD40 signalling | Q47982749 |
| | A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell | Q47982760 |
| | Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer. | Q53803561 |
| | Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. | Q54451826 |
| | CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. | Q54523129 |
| | Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. | Q55066427 |
| | Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation | Q56815463 |
| | Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines | Q56967695 |
| | Mannose receptor mediated antigen uptake and presentation in human dendritic cells | Q57275947 |
| | GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells | Q59067424 |
| | Roles of Langerhans' cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer | Q67593105 |
| | HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma--their distribution in relation to prognosis | Q67881764 |
| | Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer | Q68578875 |
| | Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance | Q70151518 |
| | Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts | Q71148644 |
| | P-glycoprotein--a marker of cancer-cell behavior | Q71523328 |
| | Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells | Q71607047 |
| | Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability | Q71615065 |
| | Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen | Q71931319 |
| | S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival | Q72379747 |
| | Infiltration of dendritic cells into regional lymph nodes in gastric cancer | Q72628437 |
| | Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis | Q72809000 |
| | Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step | Q73043181 |
| | Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells | Q73321311 |
| | Checkpoints and functional stages in DC maturation | Q73672034 |
| | Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma | Q73850975 |
| | Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients | Q74079403 |
| | Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells | Q74310288 |
| P433 | issue | 1 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 21-27 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Dendritic cells: a novel therapeutic modality | |
| P478 | volume | 10 | |